(Press-News.org) New research presented at this year’s European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes mellitus (T2DM), high blood pressure, and obstructive sleep apnoea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD) that represents the leading cause of death globally. Hence, there is a significant need to prevent CVD by targeting excess adiposity in patients with overweight or obesity.
Semaglutide is a recently approved anti-obesity medication whose cardiovascular impact in patients with and without T2DM is not well established. In this new research, the authors analysed the real-world effect of semaglutide use on the risk of CVD in patients with overweight or obesity.
They performed a multicentre retrospective study of 93 patients with a body-mass index (BMI) 27 kg/m2 or higher, age between 40-79 years, and no prior history of CVD. They collected baseline demographic, clinical, and blood fat data to calculate the 10-year atherosclerotic cardiovascular disease (10-year ASCVD) risk at baseline (i.e., before starting semaglutide) and 1 year after semaglutide initiation.
The score used is the 10-year ASCVD risk estimator created by the American College of Cardiology. The primary end point included calculating the difference in ASCVD score between baseline and after 1 year of starting semaglutide. Secondary outcomes included metabolic parameters and medication use.
Of the 93 participants, 69% were female, and the mean age was 55 years. Almost all (91%) were White. The mean BMI was 39.8kg/m2, on the borderline between class II and class III obesity.
There was a significant decrease in the 10-year ASCVD risk between baseline and 1 year: 7.64% vs 6.26%, a drop of 1.38%. The following parameters decreased significantly: blood pressure by 9.3/4.9 mmHg (for systolic and diastolic), total cholesterol by 9.5 mg/dL; LDL by 6.6 mg/dL, triglycerides by 20.0 mg/dL, fasting glucose by 23.0 mg/dL, and HbA1c (a measure of blood sugar control) by 0.72%. There was no significant change in use of blood pressure medications, statins, or aspirin between baseline and last follow-up. The total % body weight loss associated with semaglutide use at 12 months was 10.9% (across 41 patients for whom weight data was available at 12 months).
The authors conclude: “Use of semaglutide in patients with overweight or obesity is associated with a decrease in the 10-year ASCVD risk. Although modest after just one year of use, this decrease may translate into decreased cardiovascular morbidity and mortality risk over time with continuing weight loss. More studies, with larger sample sizes and longer follow-up periods, are needed to assess the cardiovascular outcomes of semaglutide.”
The authors are considering carrying out longer term studies to see if the effect of semaglutide on cardiovascular risk extends/changes over time.
Dr Andres Acosta, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA. Please e-mail to request interview. E) Acosta.Andres@mayo.edu
Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA. Please e-mail to request interview. E) ghusn.wissam@mayo.edu
Tony Kirby in the ECO Media Centre. T) +44 7834 385827 E) tony.kirby@tonykirby.com
This press release is based on poster presentation PO4.050 at the European Congress on Obesity (ECO). The material has been peer reviewed by the congress selection committee. There is no full paper at this stage.
END
Study finds cardiovascular risk score improves after one year of semaglutide use in patients with overweight and obesity
2023-05-20
ELSE PRESS RELEASES FROM THIS DATE:
Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study
2023-05-20
New research presented at this year’s European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the most recently FDA-approved anti-obesity medication. It has shown significant weight loss outcomes in multiple long-term randomised clinical trials and short-term real-world studies. However, little is known about ...
Consequences of uncontrolled hunger in teenagers living with obesity examined in international study
2023-05-20
Teenagers living with obesity who say hunger is preventing them from losing weight (hunger-barrier ALwO) perceive their weight more negatively and worry about it more than youngsters who don’t see hunger as an obstacle, new research being presented at the European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) shows.
The international study also found that hunger-barrier ALwO are more likely to be female and more likely to say their weight makes them unhappy and leads to them being bullied. They are also more likely to be actively trying to lose weight.
Dr Bassam Bin-Abbas, of the Department of Paediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, ...
Stress hormone measured in hair predicts who is likely to suffer from cardiovascular diseases
2023-05-20
New research being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) suggests that glucocorticoid levels (a class of steroid hormones secreted as a response to stress) present in the hair of individuals may indicate which of them are more likely to suffer from cardiovascular diseases (CVD) in the future.
“There is a tremendous amount of evidence that chronic stress is a serious factor in determining overall health. Now our findings indicate that people with higher long-term hair glucocorticoid ...
New high risk, high reward studies will tackle key unanswered questions about our planet
2023-05-20
NERC has invested £25 million in a host of high risk, high reward research projects to tackle critical environment challenges.
The 44 projects cover the full spectrum of environmental science including geology, atmospheric science, biodiversity and ecology.
The research will, for example:
improve our understanding of volcanic activity such as eruptions a lava flows
age the Earth’s solid inner core
investigate historic mass extinction events
predict future changes to carbon ...
A toddler’s gut bacteria predict whether they will be overweight at 5 years old
2023-05-20
The make-up and volume of gut bacteria in toddlers at 3.5 years old is predictive of body mass index (BMI) at age 5, irrespective of whether they are born prematurely or not, according to new research, being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May).
The findings also identified differences in the bacteria that colonise the gut seen in adults living with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity begin in early childhood.
The make-up of the gut microbiota grows and changes in the first few months and years of life and ...
Scientists will tune-in to the sound of the Amazon to discover how climate change and human disturbance are affecting tropical forest animals
2023-05-20
Scientists are to deploy a network of microphones in the Amazon rainforest to listen and measure the numbers and species of birds, insects and other wildlife.
The use of ‘ecoacoustics’ forms part of RAINFAUNA - a £1 million study by an international team of researchers led by scientists at Lancaster University that will provide the first large-scale understanding of how humans are affecting the animals that call tropical forests home.
Tropical forests are under threat. In the Amazon, at least 17% of primary ...
IOP Publishing celebrates 100th birthday of the oldest scientific measurement journal
2023-05-20
IOP Publishing (IOPP) is celebrating the 100th anniversary of Measurement Science and Technology, the world’s oldest scientific instrumentation and measurement journal and the first research journal produced by the Institute of Physics.
To mark the occasion, Measurement Science and Technology has pulled together a collection of articles which revisit some of the research themes published in the first volume, and looks at the latest advancements in metrology. The collection includes papers on developments in the fields of ultrasound ...
Treatment for opioid use disorder rises after Medicare OKs methadone coverage
2023-05-19
The use of methadone among Medicare beneficiaries to treat opioid use disorder increased sharply after the program began covering the drug, with evidence suggesting the change created new treatment rather than displacing use of other medications, according to a new RAND Corporation study.
Studying a large group of Medicare Advantage enrollees, the study found that a Medicare coverage expansion to include methadone in 2020 did not appear to reduce the use of buprenorphine, another medication used to treat opioid use disorder.
The study, published in the journal JAMA Network Open, found that much of the rise in methadone ...
Illinois Tech researchers unveil key predictors of bitcoin returns
2023-05-19
CHICAGO—May 19, 2023—Blockchain technology, investor sentiment, and economic stress levels are significant predictors of bitcoin returns, according to a groundbreaking paper from Illinois Institute of Technology researchers that provides empirical evidence to help guide investors, economists, and academics.
Sang Baum “Solomon” Kang, associate professor of finance at Illinois Tech’s Stuart School of Business and co-author of the paper, also found that the cryptocurrency is detached from economic fundamentals and therefore may not effectively serve as a diversifier or safe-haven asset. Additionally, Kang reported that returns on commodities, ...
SCAI announces second cycle recipients of Early Career Research Grants
2023-05-19
PHOENIX (May 19, 2023) – Today, the Society for Cardiovascular Angiography & Interventions (SCAI) announced the recipients of the second cycle of Early Career Research Grants, an initiative offered by SCAI to support the next generation of interventional cardiologists in advancing their research careers. The second cycle recipients were presented during the Early Career Award Presentations at the SCAI 2023 Scientific Sessions in Phoenix.
The Early Career Research Grants provide a platform for junior-level investigators who are within ten years of completing an interventional cardiology fellowship to study high-priority, clinically ...